NCT02511015
- Conditions
- Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +15 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
Clinical trial condition
Neuroinflammatory Diseases
Explore clinical trials studying Neuroinflammatory Diseases. Study availability and eligibility vary by location and protocol.
129 public trials
37 recruiting studies
Neuroinflammatory Diseases trial results
NCT07509372
- Conditions
- Cognition Disorders, Cognitive Dysfunction, Confusion, +16 more
- Locations
-
- Ankara University Faculty of Medicine Ankara, Turkey (Türkiye)
NCT03947827
- Conditions
- Depressive Disorder, Depressive Disorder, Treatment-Resistant, Inflammation, +8 more
- Locations
-
- Centre for Addiction and Mental Health Toronto, Ontario, Canada
NCT04266665
- Conditions
- Brain Diseases, Brain Neoplasms, Brain Tumor, +16 more
- Locations
-
- AHEPA University Hospital Thessaloniki, Greece
NCT06404203
- Conditions
- Cognitive Change, Cytokine Levels, Inflammation, +5 more
- Locations
-
- T.C. Istanbul Medipol University Istanbul, Turkey (Türkiye)
NCT07424001
- Conditions
- Delayed Neurocognitive Recovery, Inflammation, Inguinal Hernia Unilateral, +12 more
- Locations
-
- Istanbul medeniyet Universitesi Prof. Dr. Süleyman Yalçın Şehir Hastanesi Istanbul, Kadıköy, Turkey (Türkiye)
NCT07041333
- Conditions
- Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders, +7 more
- Locations
-
- Bakırköy Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospita Istanbul, Bakırkoy, Turkey (Türkiye)
NCT03341078
- Conditions
- Inflammation, Methamphetamine-dependence, Nervous System Diseases, +3 more
- Locations
-
- VA Portland Health Care System, Portland, OR Portland, Oregon, United States
NCT07346950
- Conditions
- Fibromyalgia, Inflammation, Muscular Diseases, +7 more
- Locations
-
- Uppsala University Hospital Uppsala, Sweden
Completed
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
NCT06322342
- Conditions
- Acoustic Neuroma, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, +61 more
- Locations
-
- Yale New Haven Hospital New Haven, Connecticut, United States
- Massachusetts General Hospital Boston, Massachusetts, United States
- Brigham & Women's Hospital Boston, Massachusetts, United States
- University of Missouri Columbia, Missouri, United States